US ERA ARCHIVE DOCUMENT





UNITED STATES ENVIRONMENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460

FEB 1 5 1985

MEMORANDUM

OFFICE OF
PESTICIDES AND TOXIC SUBSTANCES

SUBJECT: PP 4F3046/FAP 4H5427 and EPA Reg. No. 3125-GLR.

Cyfluthrin (Baythroid). Request for Tolerances for Residues of Cyfluthrin in/on Cottonseed, Cottonseed Oil, Cottonseed Hulls, Meat and Milk. Request for Registration of Baythroid 2 Formulated

Product.

Tox Chem No. 266E

TO:

Timothy A. Gardner, Product Manager #17

Registration Division (TS-767)

FROM:

J. D. Doherty, Ph.D.

Section II, Toxicology Branch

Hazard Evaluation Division (TS-769)

and

Edwin R. Budd, Section Head Section II, Toxicology Branch

Hazard Evaluation Division (TS-769)

THRU:

Theodore M. Farber, Ph.D.

Chief, Toxicology Branch

Hazard Evaluation Division (TS-769)

Britas

Theodore M. Farker

Requested Action:

The Mobay Chemical Corporation (Kansas City, MO) requests registration of the formulated product Baythroid 2 (EPA #3125-GLR) for use on cotton together with the following tolerances (revised May 9, 1984).

Crop	Proposed Tolerances (ppm)
Cottonseed	1.0
Meat, fat and meat byproducts of cattle, goats, hogs, horses and sheep	0.05
Milk	0.01
Cottonseed, refined, deodorized oil	2.00
Cottonseed, hulls	2.50

Cyfluthrin is a new synthetic pyrethroid insecticide. This is the first request for permanent tolerances for this chemical.

Conclusions:

- 1. All toxicology studies required to support the proposed registration of Baythroid 2 for use on cotton (only) and the requested tolerances have been submitted to and have been reviewed by Toxicology Branch.
 - NOTE: Toxicology Branch was informed by Chris Dively (PM Team ±17) on 1/31/85 that she had spoken with G.E. Brussell (Mobay Chemical Corporation) on 1/31/85 and that he had assured her that the formulated product described in this review as Baythroid 240 EC and the formulated product for which registration is proposed for use on cotton (i.e. Baythroid 2, EPA #3125-GLR) are identical and that only the "name" had been changed. Toxicology Branch requests that Mobay be asked by Registration Division to verify this statement in writing prior to registration of Baythroid 2 for use on cotton.
- 2. Toxicology Branch has no objection to the proposed registration and tolerances provided that the following requirements are adequately addressed and responses submitted to Toxicology Branch within a reasonable period of time. It is not necessary that this be done prior to registration of Baythroid 2 for use on cotton or prior to establishment of the tolerances. In other words, the following are "conditional requirements."
 - a. Many of the toxicology studies were <u>not signed</u> by the persons responsible for the work. Signed reports of these studies must be submitted to EPA. Failure to submit the signed reports will result in reclassification of the studies to INVALID status.
 - b. Neurotoxicity studies in chickens. Cyfluthrin was tested in several studies for possible delayed type neurotoxicity. Evidence of nerve fiber degeneration was noted in some of these studies. The data generated thus far are not conclusive with respect to determining the potential for cyfluthrin to produce delayed type neurotoxicity in chickens.

The registrant is requested to conduct an additional study to assist in determining the potential of cyfluthrin to affect the nervous system. This study should be a "hen brain neurotoxic esterase" study. It is strongly suggested that the registrant, prior to performing this study, submit the proposed protocol to Toxicology Branch for comment.

Toxicology Branch does not consider the inconclusive results of the acute delayed neurotoxicity tests in chickens to be of sufficient concern at this time to warrant delaying the registration of this product and the associated tolerances. Considerable toxicology data in mammalian species is presently available which does not suggest an unreasonable potential hazard to the nervous system of humans under conditions of use. Toxicology Branch considers the latter evidence to be more relevant to its determination of potential hazards to humans.

Nevertheless, in order to assist in the resolution of this outstanding issue, the "hen brain neurotoxic esterase study" is required to be performed and submitted.

It is suggested that the registrant consider information presented in the following reference when designing the "hen brain neurotoxic esterase study."

Johnson, M. K., Structure-activity relationships for substrates and inhibitors of hen brain neurotoxic esterase, Biochem. Pharmacol., 24: 797-805, 1975.

This study should include a negative control group and a positive control group of hens. Toxicology Branch is aware that relatively few toxicology laboratories are prepared to perform this type of study. Nevertheless, a few do. If requested by the registrant, Toxicology Branch will supply the names of some laboratories that have the capability of performing this study. Toxicology Branch is also willing to discuss with the registrant, if requested, problems that may arise during the design and/or performance of this study.

The registrant is also requested to provide an explanation and/or rationale for the different results observed in the acute delayed neurotoxicity tests in chickens between the studies performed by Bayer AG Institute of Toxicology (in Germany) and those performed by Mobay Chemical Corporation (in the United States). Some points that should be addressed include:

- Possible differences in the test material
 - Including a consideration of impurities, contaminants and/or manufacturing by-products in the test material.
 - Including a consideration of possibly different ratios of active ingredient isomers in the test material.
- Possible differences in the test animals used
 - o Including a consideration of strain, source, etc.
 - Including a consideration of normal background incidence of nervous system lesions in historical control animals of the same strain and source (if possible).
- Possible differences in investigational techniques employed.
- Other

c. Mutagenicity Studies:

The following additional mutagenicity studies are required:

- gene mutation in mammalian cells in culture
- cytogenetics assay in mammalian cells in culture
- DNA repair assay in mammalian cells in culture.
- 3. The inerts in the formulated product BAYTHROID 2 are cleared for the proposed use.
- 4. The following changes in the precautionary statements are recommended.

Add "May be fatal if inhaled." [Note: the product is Tox. Cat. II by inhalation exposure.]

Delete "No specific symptoms. Acute poisoning accompanied by general depression and illness."

Unverified Printout

ACCEPTABLE DAILY INTAKE DAWRAFT

004285

FAT, Claer NOEL mg/kg chw

S.F.

AbI mg/kg/day mg/day (60kg)

MPI

2.500

50.00

100

0.0250

1.5000

Current Action

4F3046/4H5427

CROP Ccttcnseed (oil) (41)

Tolerance Food Factor mg/day (1.5kg) 2.000

0.15

0.00450

Leat, rec(90) Milk&Dairy Products (93)

0,050 0.010 10.81 23.62 0.00811 0.00429

THRC 1.5000 mg/day(60kg) 0.0169 mg/day(1.5kg) % ADI

8-Point Review

1. Toxicity data with technical grade cyfluthrin considered in support of this tolerance (selected studies).

Acute Oral LD50, rats LD50 = 590 mg/kg, malesLD50 = 1.189 mg/kg, females

LD50 = 291 mg/kg, malesAcute Oral LD50, mice LD50 = 609 mg/kg, females

LD50 > 5,000 mg/kg, males and females Acute Dermal LD50, rats

LC50 > 1.089 mg/L, males and females Acute Inhalation LC50, rats

Dermal Sensitization, guinea pigs

Not a sensitizer

90-Day Feeding, rats NOEL = 300 ppm (HDT)

6-Month Feeding, dogs NOEL = 200 ppmLOEL = 600 ppm

NOEL = 160 ppm12-Month Feeding, dogs LOEL = 640 ppm

2-Year Feeding/Oncogenicity, rats

Not oncogenic at dosage levels up to and including 450 ppm (HDT)

NOEL = 50 ppm (or 2.5 mg/kg/day)

LOEL = 150 ppm

23-Month Oncogenicity, mice

Not oncogenic at dosage levels up to and

including 800 ppm (HDT)

3-Generation Reproduction, rats

NOEL = 50 ppmLOFL = 150 ppm

Teratology, rats

Not teratogenic at dosage levels up to and

including 30 mg/kg/day (HDT)

Teratology, rabbits

Not teratogenic at dosage levels up to and

including 45 mg/kg/day (HDT)

Delayed Neurotoxicity, hens (oral administration)

Inconclusive results.

Delayed Neurotoxicity, hens (dermal administration)

Negative for delayed effects on the nervous system

8-Point Review (contd.)

21-Day Inhalation, hens

Negative for delayed effects on the nervous

system

5-Month Neurotoxicity, rats

Negative for delayed effects on the nervous

system

Mutagenicity Studies:

Reverse Mutation Assays (with and without metabolic activation).

S. typhimurium

Negative

E. coli

Negative

S. cerevisiae

Negative

Recombination Assays

B. subtilis

Negative

S. cerevisiae

Negative

- Additional toxicity data considered desirable ("conditional requirements"

 see "Conclusions", above)
 - a. "Hen brain neurotoxic esterase" study

(see "Conclusions")

- b. Gene mutation in mammalian cells in culture
- c. Cytogenetic assay in mammalian cells in culture
- d. DNA repair assay in mammalian cells in culture
- 3. The above additional toxicity studies are requested in this review.
- 4. This is the first F petition for cyfluthrin.
- 5. Establishing these tolerances will result in 1.13% of the MPI being used up. (See computer printout, attached.)
- 6. The 2-year chronic feeding/oncogenicity study in rats with a NOEL of 50 ppm (equal to 2.5 mg/kg/day) and a safety factor of 100 were used to calculate the ADI (0.025 mg/kg/day). The MPI is 1.50 mg/day (60 kg).
- 7. There are no pending regulatory actions against the registration of cyfluthrin.
- 8. None.

Studies Reviewed

STUDIES WITH BAYTHROID TECHNICAL

	<u> </u>	
Study	Results	Core Classification
Acute Toxicity		
Acute Oral LD ₅₀ - rats (fasted)	Males: 590 (509-695) mg/kg (in polyethylene glycol 400)	Minimum
	Females: 1189 (1002-1443) mg/l (in polyethylene glycol 400)	kg Minimum
Acute Oral LD ₅₀ - rats (unfasted)	Males: 869 (685-1051) mg/kg (in polyethylene glycol 400)	Minimum
	Females: 1271 (1102-1456) mg/(in polyethylene glycol 400)	kg Minimum
Acute Oral LD ₅₀ - rats	16.2 (13.5-19.5) mg/kg males (in Cremophor EL/dist. H ₂ O)	Minimum
Acute Oral LD ₅₀ - rats	254 (220-294) mg/kg males (in acetone)	Minimum
Acute Oral LD ₅₀ - rats	396 (317-494) mg/kg males (in DMSO)	Minimum
Acute Oral LD ₅₀ - rats	500-1000 mg/kg males (in n-methyl-pyrollidon)	Minimum
Acute Oral LD ₅₀ - mice	Males: 291 (202-413) mg/kg (in polyethylene glycol 400)	Minimum
	Females: 609 (432-827) mg/kg (in polyethylene glycol 400)	Minimum
Acute Oral LD ₅₀ - mice	<100 mg/kg - females (in Cremophor EL/dist. H ₂ O)	Minimum
Acute Oral LD ₅₀ - rabbits	>1000 mg/kg - (males only) No rabbits died	Minimum
Acute Oral LD ₅₀ - dogs	>100 mg/kg (?) - (males only) No dogs died, but both dogs vomited at this level	Minimum
Acute Oral LD ₅₀ — dogs	Salivation and vomiting at 20 and 100 mg/kg. No deaths	Supplementary
Acute Oral LD ₅₀ - sheep	$LD_{50} = 1000 \text{ mg/kg}$	Minimum

Study	Results	Core Classification
Acute Intraperitoneal (IP) LD ₅₀ - rats	Males: 66 (53-84) mg/kg Females: 104 (76-135) mg/kg	Acceptable
Acute IP - rats	20 (17-22) - males 24 (21-28) - females (in Cremophor EL/dist H ₂ 0)	Acceptable
Acute IP - rats	34 (30-37) - males 96 (68-131) - females (in polyethylene glycol)	Acceptable
Acute Subcutaneous LD ₅₀ - mice	>2,500 mg/kg for both sexes (no deaths)	**************************************
Acute Dermal LD50 - rats	>5,000 mg/kg for both sexes	Minimum
Acute Dermal LD ₅₀ - rats	>5,000 mg/kg in either Cremophor EL/dist. H ₂ O, 0.9% NaCl, or undiluted	Minimum
Acute Inhalation LC ₅₀ - rats (in ethanol/lutrol) one hour exposure	$LC_{50} > 1.089 \text{ mg/m}^3 (1.089 \text{ mg/L})$ (no deaths)	Minimum
Acute Inhalation LC ₅₀ - rats (in aqueous Crem-ophor) 4 hour exposure	LC_{50} Males - >735 mg/m ³ Females - 200-735 mg/m ³	Minimum
Acute Inhalation LC ₅₀ - rats (DMSO/Lutrol) 4 hour exposure	$IC_{5()}$ Males - 575 (458-722) mg/m ³ Females - 490 (412-582) mg/m ³	Minimum
Acute Inhalation IC ₅₀ - rats (in ethanol/ Lutrol) 4 hour exposure	$LC_{50} = 469-592 \text{ mg/m}^3$	Minimum
Acute Inhalation LC ₅₀ - chickens (in ethanol/Lutrol) 4 hour exposure	IC ₅₀ >596 mg/m ³ No hens died	Minimum
Acute Inhalation LC ₅₀ - rats (in ethanol/ Lutrol) 4 hour exposure	$LC_{50} < 596 \text{ mg/m}^3$	Minimum
Acute Inhalation IC ₅₀ - rats (in ethanol/Lutrol) 5 six hour exposures	$LC_{50} = 47-196 \text{ mg/m}^3$	- Minimum

Study_	Results	Core Classification
Dermal irritation - rabbits	PIS = 0	Minimum
Dermal irritation - rabbits	PIS = 0.25	Invalid
Eye irritation - rabbits	Transient irritation only	Minimum
Eye irritation - rabbits	Mildly irritating No corneal opacity	Invalid
Deimal sensitization - guinea pigs - (Draize type)	Not a sensitizer	Minimum
Dermal sensitization - guinea pigs - (Maximization Test)	Not a sensitizer	Guidelines
Dermal sensitization - guinea pigs -	Not a sensitizer	Invalid
Antidote study - rats	Musaril (a.i. tetrazepam, a benzodiazapine) was effective in changing the LD ₅₀ observed.	Minimum
Thiocyanate excretion - rats	Thiocyanate in urine could not be correlated with toxicity of cyfluthrin or deltamethrin.	Minimum
Absorption study - rats	Cyfluthrin is absorbed from the GI tract more rapidly when administered in Cremophor than when in polyethylene glycol - 400	
Short-Term Studies		
28—day subacute oral toxicity — rats (gavage) (with recovery phase)	NOEL = 20 mg/kg/day LEL = 40 mg/kg/day (Nerve stimulation, body weigh loss, liver and adrenal weight changes)	
90—day feeding — rats	NOEL = 300 ppm (HDT). No definite test chemi effects noted	Minimum cal
28-day feeding - rats (with recovery phase)	NOEL = 100 ppm LEL = 300 ppm (minimal decreas in blood glucose)	Supplementary e

Study

Results

Core Classification

AT 1000 ppm (HDT) behavioral changes, body weight loss, urobilinogen and ketone bodies in urine, decreased RBC, hematocrit and hemoglobin counts, increased weights of submaxillary glands (also had cytoplasmic swelling) liver weight change. Some evidence of single nerve fiber degeneration in the sciatic nerve which was not evident in the recovered rats.

28-day feeding - mice (with recovery phase)

NOEL = 300 ppm

LEL = 1000 ppm (behavioral changes, decreased body weight gain, increased liver weight, cytoplasmic swelling of the sübmaxillary glands). At 3000 ppm (HDT) - in addition to above, possible decrease in WBC, increase in "AIP" and BUN, increased weight of submaxillary glands, decreased spleen, adrenal and ovary weights.

21-day subacute dermal - rabbits NOEL = 250 mg/kg/day (HDT)

Minimum

Supplementary

21 day subacute - inhalation - rats

NOEL = 1.4 mg/m^3 Minimum LEL = 2.3 mg/m^3 (decreased body weight gain). At $\geq 10.5 \text{ mg/m}^3$, there were behavioral changes, body weight changes and organ weight changes in liver, spleen, and possibly other organs.

21-day subacute inhalation chickens 1 death at 614 mg/m³ Nonspecific symptomology at this level. Minimum

Long-Term Studies

6-month feeding - dogs

NOEL = 200 ppm LEL = 600 ppm (stiff gait, uncoordination, arched backs late in study, vomiting, diarrhea, possibly decreased thymus weights) Minimum

Study	Results	Core Classification
12-month feeding - dogs	NOEL = 160 ppm LEL = 640 ppm (slight ataxia in 2 animals on 1 occasion each increased vomiting and diarrhed decreased body weights in males	а,
3-generation reproduction - rats	NOEL = 50 ppm for reproductive effects LEL = 150 ppm (decreased viabilities, some pup deaths) NOEL = 50 ppm for systemic effectin pups LEL = 150 ppm (body weight decreased viabilities)	ects
5-month neuro- toxicity - rats	Not neurotoxic (axonal degeneration myelin effects) at 60/80 mg, day orally by gavage for 5 months.	/kg/
Teratology - rats	No teratogenic effects noted up to and including 30 mg/kg/day (HDT).	Minimum
Teratology - rabbits	No teratogenic effects noted up to and including 45 mg/kg/da(HDT)	
2-year chronic feeding/oncogeni- city - rats	Not oncegenic at deses up to a including 450 ppm (HDT). NOEL 50 ppm. LOEL = 150 ppm (decrebody weights in males, inflammation in kidneys of females)	= chronic toxicity ased
23-month chronic feeding/oncogeni- city - mice	Not oncogenic at doses up to a including 800 ppm (HDT). NOEL < 50 ppm. LOEL = 50 ppm (increalkaline phosphatase activity males)	for chronic eased toxicity
Delayed type neuro- toxicity - hens (oral) - single dose	LD ₅₀ about 5000 mg/kg (in poly ethylene glycol 400). Behavor changes in 2/10 hens and some signs of nerve fiber degenerat reported ("moderate" in degree	ial ion

Study	Results	Core Classification
Delayed type neuro- toxicity - hens (oral) - multi dose (2 doses)	Pehavorial changes in 4 hens. Nerve fiber degeneration in majority of treated hens.	Supplementary
Delayed type neuro- toxicity - hens (oral) - multi dose (5 doses)	Rehavorial changes in 3/6 surviving hens. Nerve fiber degeneration also observed.	Supplementary
toxicity - hens (oral) - single dose	No behavorial changes. No microscopy of nervous tissue performed. Dose was 5000 mg/k	Supplementary g.
Delayed type neuro- toxicity - hens (oral) - multi dose (2 doses)	Negative for behavioral and microscopic changes in nervous tissue. Dose was 5000 mg/kg	Minimum
Delayed type neuro- toxicity - hens (dermal)	No evidence of delayed neuro- toxicity by the <u>dermal</u> route.	Minimum
Mutagenicity Studies:	/	
Mutagenic - <u>Salmonella</u> microsome	Negative for <u>S</u> . <u>typhimurium</u> TA-1535, 1537, 100, and 98 strains, with and without metabolic activation.	(macceptable
Mutagenic - Micronucleus test: mice	Negative for hematopoietic effect in NMRI/ORIG Kisslegg mice.	Unacceptable
Mutagenic - Dominant lethal test; mice	Systemic NOEL > 60 mg/kg (Embryotoxic NOEL > 60 mg/kg (Reproductive NOEL > 60 mg/kg (X1)
Mutagenic - Differential Bacterial Toxicity test	Negative for E. coli pol A, pol A+ strains with and without metabolic activation.	and Acceptable ut

Study	Results	Core Classification
Mutagenic - Bacterial mutagenicity tests	Rec-Assay - Negative for NIG 45 and NIG 17 Bacillus subtilis strains.	Unacceptable
1	Reversion Assay - Negative for S. typhimurium TA- 1535, 1537, 1538, 98, and 100 strains and E. coli B/r WP2 try her strain, with and without metabolic activation.	Acceptable
Mutagenic - Microbial mutagenicity	Rec-Assay - Negative for H17 ar M45 Bacillus subtilis strains	
<u>.</u>	Reversion Assay - Negative for S. typhimurium TA- 1535, 1537, 1538, 98, and 100 strains and E. coli WP2 her strain, wi and without metabolic activation	Acceptable th
Mutagenic - Reverse mutation induction	Cytotoxicity Study - Not cytoto for S. cerevisiae S211	xic Acceptable
	Reverse Mutation Assay - Negati for S2ll and Sl38 strains of Saccharomyces cerevisiae with a without metabolic activation.	
Mutagenic - Recombin- nation and conversion assays	Cytotoxicity Study - Not cytoto for D ₇ strain of Saccharomyces cerevisiae	
	Recombination and Conversion - negative for D ₇ strain of Saccharomyces cerevisiae	Acceptable
STUDIES WITH BAYTHROID 240 EC (Baythroid 2)		
Acute Oral LD ₅₀ - rats	$LD_{50} = 1015 (651-1671) \text{ mg/kg} - \text{males.} LD_{50} = 826 (598-1225) - \text{females}. \text{Tox Cat III}$	Minimum
Acute Dermal LD ₅₀ - rabbits	LD ₅₀ >2000 mg/kg both sexes. Tox Cat III	Minimum
Acute Inhalation IC ₅₀ - rats	$LC_{50} = 1323 (1138-1505) \text{mg/m}^3 - \text{males.}$ 1434 (1153-1877) mg/m^3 - females Tox Cat II	Guidelines
Primary Eye Irrita- tion - rabbits	Corneal opacity >21 days. Tox Cat I	Guidelines
Primary Dermal Irritation — rabbits	Pl1 = 0.8 (4 hour exposure). Tox Cat IV	Guidelines